Protagonist Therapeutics 2024 Company Overview Presentation

Protagonist Therapeutics presents its core competencies in peptide-based medicine development, featuring lead programs including JNJ-2113 for psoriasis in Phase 3 trials and rusfertide for polycythemia vera. The presentation outlines the company's expertise in peptide chemistry, oral stability, and GI-restricted targeted delivery, supported by a collaboration with Janssen Biotech.